Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Norcantharidin Lipid Microsphere for Injection
- Development stage
- Phase 1
- Lead developer
- Beijing Nuokangda Pharmaceutical Technology
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Norcantharidin Lipid Microsphere for Injection is an intravenous formulation of norcantharidin (NCTD), a synthetic demethylated derivative of cantharidin, developed by Beijing Nuokangda Pharmaceutical Technology. The drug is encapsulated within lipid microspheres—an oil-in-water emulsion system typically composed of soybean oil and lecithin—to enhance its solubility, improve bioavailability, and mitigate the severe nephrotoxicity and cardiotoxicity associated with traditional norcantharidin salts. Norcantharidin functions as a small molecule inhibitor of protein phosphatase 2A (PP2A), a key regulator of signaling pathways involved in cell growth and survival. By inhibiting PP2A, the drug induces G2/M phase cell cycle arrest and triggers apoptosis in malignant cells. This formulation is currently being evaluated in Phase I clinical trials for the treatment of locally advanced or metastatic solid tumors.
- Other names
- Norcantharidin lipid microsphereNCTD-LM
02
Targets
EZH2 (Histone-lysine N-methyltransferase EZH2)PP1 (Protein phosphatase 1)PP2A (Protein phosphatase 2A)
Beyond the preview
Go deeper on Norcantharidin Lipid Microsphere for Injection.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Norcantharidin Lipid Microsphere for Injection.